Reynolds Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Reynolds Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,300	Closed	-$241K	–	117
2015 Q4	$241K	Buy	+2,300	New	+$240K	0.26%	114
2015 Q3	–	Sell	-3,200	Closed	-$438K	–	142
2015 Q2	$438K	Sell	3,200 -600	-16%	-$74.4K	0.43%	77
2015 Q1	$474K	Buy	3,800 +1,300	+52%	+$138K	0.41%	75
2014 Q4	$226K	Buy	+2,500	New	+$208K	0.19%	208
2013 Q4	–	Sell	-5,100	Closed	-$368K	–	439
2013 Q3	$368K	Buy	5,100 +1,200	+31%	+$79.8K	0.24%	144
2013 Q2	$218K	Buy	+3,900	New	+$243K	0.16%	293

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Reynolds Capital Management's BMRN Position: Q1 2016 in Review

Reynolds Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 2,300 shares — an estimated $241K sold.

Reynolds Capital Management first reported a position in BMRN in Q2 2013 and held it in 6 quarters. The position peaked at $474K in Q1 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Reynolds Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Reynolds Capital Management sold 2,300 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $241K.
Reynolds Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Reynolds Capital Management's BioMarin Pharmaceuticals position peaked at $474K in Q1 2015.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Reynolds Capital Management's 13F filing for Q1 2016, filed 13 May 2016.